Eisai and Biogen: Lecanemab for the Treament of Early Alzheimer’s DIisease
May 10, 2022
0
Eisai and Biogen Inc: Lecanemab Eisai and Biogen Inc. (BIIB) announced that Eisai has completed the rolling submission to the U.S. FDA of a Biologics License Application (BLA) under the accelerated approval pathway for the investigational anti-amyloid beta (Aβ) protofibril antibody lecanemab (BAN2401). The product is for mild cognitive impairment due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD) with confirmed presence …